ABL1 and acute lymphoblastic leukemia: The study also found a high incidence of recurrent IKZF1 deletions in ABL-class patients consistent with a previous report of 40% IKZF1 deletions in Ph-like ALL [11] and demonstrated effective use of these markers to monitor disease.